Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itanapraced in Mild Cognitive Impairment
NCT01303744Phase 2Completed
- Sponsor
- CereSpir
- Start
- Mar 2011
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Itanapraced in Mild Cognitive Impairment (MCI) (4 arms), sponsored by CereSpir. Primary endpoint: Differences in ∆sCD40L Levels at 12 weeks. Started Mar 2011; status: completed.
02
Drugs
Itanapraced
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT01303744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01303744.